1 / 6

Prior posts at the Edouard-Herriot Hospital and the Centre Hospitalier Lyon-Sud, Lyon, France

Bertrand Coiffier Professor, Department of Haematology, Hospices Civils de Lyon and University Claude Bernard, Lyon, France. Prior posts at the Edouard-Herriot Hospital and the Centre Hospitalier Lyon-Sud, Lyon, France

arnaud
Download Presentation

Prior posts at the Edouard-Herriot Hospital and the Centre Hospitalier Lyon-Sud, Lyon, France

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Bertrand CoiffierProfessor, Department of Haematology, Hospices Civils de Lyon and University Claude Bernard, Lyon, France • Prior posts at the Edouard-Herriot Hospital and the Centre Hospitalier Lyon-Sud, Lyon, France • Member of the American Society of Hematology, the American Society of Clinical Oncology, the International Society for Medical Oncology, and the European Haematology Association • Founding member of the Group d’Etude des Lymphomes de l’Adulte (GELA) and the European Task Force on Lymphoma Université Claude Bernard

  2. Chair’s openingChallenges for the treatment of Non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia Bertrand Coiffier Centre Hospitalier Lyon-SudLyon, France

  3. 11.30 Chair’s openingBertrand Coiffier 11.35 Rituximab in aggressive NHL: why combination therapy should not be delayedBertrand Coiffier 12.05 Indolent NHL: a survival benefit with rituximab-based therapyChristian Buske 12.35 Discussion 12.50 Lunch 14.30 Meet the Expert sessions 15.30 Coffee break 16.00 Maintenance treatment in follicular lymphoma: indications and considerationsMarinus van Oers 16.30 CLL treatment today and tomorrow: the role of rituximabStephen Mulligan 16.55 Management of relapsed CLL: why rituximab?John Gribben 17.15 Discussion and close Friday 8 February 2008Agenda

  4. NHL and CLL: introduction • NHL and CLL are cancers that affect B-and T-lymphocytes • NHLs are a heterogenous group of diseases withtwo major subtypes • indolent • aggressive • CLL is also heterogenous but in the majority of patients behaves like an indolent lymphoma withslow progression

  5. NHL: what are the challenges that we face in the next decade? • Establishing optimal therapeutic combinations in the treatment of advanced stage follicular lymphoma • Defining the role of maintenance therapy in follicular lymphoma • Identifying optimal treatment strategies for young patients with high-risk DLBCL • Prognostic factors in DLBCL: is clinical risk-adapted therapy a viable option? • Optimal management of medically non-fit patients with follicular lymphoma DLBCL = Diffuse Large B Cell Lymphoma

  6. CLL: what are the challenges that we face in the next decade? • Determining the therapeutic options for patients with fludarabine-refractory CLL • Identifying optimal management strategies for elderly patients with CLL and renal impairment • Determining when CLL treatment should be initiated • Establishing whether novel prognostic factors should be integrated into treatment decisions for CLL • Optimal management of patients with relapsed CLL

More Related